469 related articles for article (PubMed ID: 35711434)
1. The Role of Myeloid Cells in GBM Immunosuppression.
Lin YJ; Wu CY; Wu JY; Lim M
Front Immunol; 2022; 13():887781. PubMed ID: 35711434
[TBL] [Abstract][Full Text] [Related]
2. Myeloid Cells in Glioblastoma Microenvironment.
De Leo A; Ugolini A; Veglia F
Cells; 2020 Dec; 10(1):. PubMed ID: 33374253
[TBL] [Abstract][Full Text] [Related]
3. Role of myeloid cells in the immunosuppressive microenvironment in gliomas.
Locarno CV; Simonelli M; Carenza C; Capucetti A; Stanzani E; Lorenzi E; Persico P; Della Bella S; Passoni L; Mavilio D; Bonecchi R; Locati M; Savino B
Immunobiology; 2020 Jan; 225(1):151853. PubMed ID: 31703822
[TBL] [Abstract][Full Text] [Related]
4. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs.
Lakshmanachetty S; Cruz-Cruz J; Hoffmeyer E; Cole AP; Mitra SS
Cells; 2021 Apr; 10(4):. PubMed ID: 33919732
[TBL] [Abstract][Full Text] [Related]
5. Glioma-associated microglia/macrophages (GAMs) in glioblastoma: Immune function in the tumor microenvironment and implications for immunotherapy.
Lin C; Wang N; Xu C
Front Immunol; 2023; 14():1123853. PubMed ID: 36969167
[TBL] [Abstract][Full Text] [Related]
6. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts.
Yabo YA; Moreno-Sanchez PM; Pires-Afonso Y; Kaoma T; Nosirov B; Scafidi A; Ermini L; Lipsa A; Oudin A; Kyriakis D; Grzyb K; Poovathingal SK; Poli A; Muller A; Toth R; Klink B; Berchem G; Berthold C; Hertel F; Mittelbronn M; Heiland DH; Skupin A; Nazarov PV; Niclou SP; Michelucci A; Golebiewska A
Genome Med; 2024 Apr; 16(1):51. PubMed ID: 38566128
[TBL] [Abstract][Full Text] [Related]
8. Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells.
Hasan MN; Luo L; Ding D; Song S; Bhuiyan MIH; Liu R; Foley LM; Guan X; Kohanbash G; Hitchens TK; Castro MG; Zhang Z; Sun D
Theranostics; 2021; 11(3):1295-1309. PubMed ID: 33391535
[No Abstract] [Full Text] [Related]
9. Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma.
Won WJ; Deshane JS; Leavenworth JW; Oliva CR; Griguer CE
Cell Stress; 2019 Jan; 3(2):47-65. PubMed ID: 31225500
[TBL] [Abstract][Full Text] [Related]
10. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
Kamran N; Chandran M; Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics.
Ye Z; Ai X; Zhao L; Fei F; Wang P; Zhou S
Oncogene; 2021 Oct; 40(42):6059-6070. PubMed ID: 34556813
[TBL] [Abstract][Full Text] [Related]
12. Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.
Pang L; Khan F; Heimberger AB; Chen P
Trends Cancer; 2022 Oct; 8(10):839-854. PubMed ID: 35624002
[TBL] [Abstract][Full Text] [Related]
13. Immune microenvironment of gliomas.
Gieryng A; Pszczolkowska D; Walentynowicz KA; Rajan WD; Kaminska B
Lab Invest; 2017 May; 97(5):498-518. PubMed ID: 28287634
[TBL] [Abstract][Full Text] [Related]
14. Global stability and parameter analysis reinforce therapeutic targets of PD-L1-PD-1 and MDSCs for glioblastoma.
Anderson HG; Takacs GP; Harris DC; Kuang Y; Harrison JK; Stepien TL
J Math Biol; 2023 Dec; 88(1):10. PubMed ID: 38099947
[TBL] [Abstract][Full Text] [Related]
15. Immune suppression in gliomas.
Grabowski MM; Sankey EW; Ryan KJ; Chongsathidkiet P; Lorrey SJ; Wilkinson DS; Fecci PE
J Neurooncol; 2021 Jan; 151(1):3-12. PubMed ID: 32542437
[TBL] [Abstract][Full Text] [Related]
16. Systemic and local immunosuppression in glioblastoma and its prognostic significance.
Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Abramova OV; Pavlov KA; Chekhonin VP
Front Immunol; 2024; 15():1326753. PubMed ID: 38481999
[TBL] [Abstract][Full Text] [Related]
17. The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia.
Arrieta VA; Najem H; Petrosyan E; Lee-Chang C; Chen P; Sonabend AM; Heimberger AB
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948178
[TBL] [Abstract][Full Text] [Related]
18. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
19. Immunogenomic analysis reveals LGALS1 contributes to the immune heterogeneity and immunosuppression in glioma.
Chen Q; Han B; Meng X; Duan C; Yang C; Wu Z; Magafurov D; Zhao S; Safin S; Jiang C; Cai J
Int J Cancer; 2019 Jul; 145(2):517-530. PubMed ID: 30613962
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts.
Yabo YA; Moreno-Sanchez PM; Pires-Afonso Y; Kaoma T; Nosirov B; Scafidi A; Ermini L; Lipsa A; Oudin A; Kyriakis D; Grzyb K; Poovathingal SK; Poli A; Muller A; Toth R; Klink B; Berchem G; Berthold C; Hertel F; Mittelbronn M; Heiland DH; Skupin A; Nazarov PV; Niclou SP; Michelucci A; Golebiewska A
bioRxiv; 2023 Dec; ():. PubMed ID: 36945572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
